|
1
|
Pritchard JE, Dillon PM, Conaway MR, Silva
CM and Parsons SJ: A mechanistic study of the effect of
doxorubicin/adriamycin on the estrogen response in a breast cancer
model. Oncology. 83:305–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Borges S, Döppler H, Perez EA, Andorfer
CA, Sun Z, Anastasiadis PZ, Thompson E, Geiger XJ and Storz P:
Pharmacologic reversion of epigenetic silencing of the PRKD1
promoter blocks breast tumor cell invasion and metastasis. Breast
Cancer Res. 15:R662013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bombonati A and Sgroi DC: The molecular
pathology of breast cancer progression. J Pathol. 223:307–317.
2011. View Article : Google Scholar :
|
|
4
|
Zeng T and Liu J: Mixture classification
model based on clinical markers for breast cancer prognosis. Artif
Intell Med. 48:129–137. 2010. View Article : Google Scholar
|
|
5
|
Vuong D, Simpson PT, Green B, Cummings MC
and Lakhani SR: Molecular classification of breast cancer. Virchows
Arch. 465:1–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dumay A, Feugeas JP, Wittmer E,
Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M,
André F, et al: Distinct tumor protein p53 mutants in breast cancer
subgroups. Int J Cancer. 132:1227–1231. 2013. View Article : Google Scholar
|
|
7
|
Zhang X, Jin G, Li J and Zhang L:
Association between four MMP-9 polymorphisms and breast cancer
risk: A meta-analysis. Med Sci Monit. 21:1115–1123. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Turkoz FP, Solak M, Petekkaya I, Keskin O,
Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y and Altundag K:
Association between common risk factors and molecular subtypes in
breast cancer patients. Breast. 22:344–350. 2013. View Article : Google Scholar
|
|
9
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the Carolina
Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arveux P and Bertaut A: Epidemiology of
breast cancer. Rev Prat. 63:1362–1366. 2013.(In French).
|
|
11
|
Tehranifar P, Reynolds D, Fan X,
Boden-Albala B, Engmann NJ, Flom JD and Terry MB: Multiple
metabolic risk factors and mammographic breast density. Ann
Epidemiol. 24:479–483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vadaparampil ST, Quinn GP, Miree CA,
Brzosowicz J, Carter B and Laronga C: Recall of and reactions to a
surgeon referral letter for BRCA genetic counseling among high-risk
breast cancer patients. Ann Surg Oncol. 16:1973–1981. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li N, Zhou P, Zheng J, Deng J, Wu H, Li W,
Li F, Li H, Lu J, Zhou Y, et al: A polymorphism rs12325489C>T in
the lincRNA-ENST00000515084 exon was found to modulate breast
cancer risk via GWAS-based association analyses. PLoS One.
9:e982512014. View Article : Google Scholar :
|
|
14
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stefansson OA and Esteller M: Epigenetic
modifications in breast cancer and their role in personalized
medicine. Am J Pathol. 183:1052–1063. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cianfrocca M and Goldstein LJ: Prognostic
and predictive factors in early-stage breast cancer. Oncologist.
9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Castellano I, Chiusa L, Vandone AM,
Beatrice S, Goia M, Donadio M, Arisio R, Muscarà F, Durando A,
Viale G, et al: A simple and reproducible prognostic index in
luminal ER-positive breast cancers. Ann Oncol. 24:2292–2297. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang J, Clark GM, Allred DC, Mohsin S,
Chamness G and Elledge RM: Survival of patients with metastatic
breast carcinoma: Importance of prognostic markers of the primary
tumor. Cancer. 97:545–553. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Higa GM and Fell RG: Sex hormone receptor
repertoire in breast cancer. Int J Breast Cancer. 2013:2840362013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Borg A, Tandon AK, Sigurdsson H, Clark GM,
Fernö M, Fuqua SA, Killander D and McGuire WL: HER-2/neu
amplification predicts poor survival in node-positive breast
cancer. Cancer Res. 50:4332–4337. 1990.PubMed/NCBI
|
|
21
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J:
CCNA2 is a prognostic biomarker for ER+ breast cancer
and tamoxifen resistance. PLoS One. 9:e917712014. View Article : Google Scholar
|
|
22
|
Sahab ZJ, Man YG, Byers SW and Sang QX:
Putative biomarkers and targets of estrogen receptor negative human
breast cancer. Int J Mol Sci. 12:4504–4521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Akin S, Babacan T, Sarici F and Altundag
K: A novel targeted therapy in breast cancer: Cyclin dependent
kinase inhibitors. J BUON. 19:42–46. 2014.PubMed/NCBI
|
|
24
|
Muellner MK, Uras IZ, Gapp BV,
Kerzendorfer C, Smida M, Lechtermann H, Craig-Mueller N, Colinge J,
Duernberger G and Nijman SM: A chemical-genetic screen reveals a
mechanism of resistance to PI3K inhibitors in cancer. Nat Chem
Biol. 7:787–793. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
American Cancer Society. 2013, Breast
Cancer Facts and Figures 2013–2014. Atlanta: American Cancer
Society; 2013, http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf.
|
|
26
|
World Health Organization (WHO).
Guidelines for management of breast cancer. 2006, http://applications.emro.who.int/dsaf/dsa697.pdf.
|
|
27
|
Dawood S, Broglio K, Gonzalez-Angulo AM,
Buzdar AU, Hortobagyi GN and Giordano SH: Trends in survival over
the past two decades among white and black patients with newly
diagnosed stage IV breast cancer. J Clin Oncol. 26:4891–4898. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Borges S, Döppler HR and Storz P: A
combination treatment with DNA methyltransferase inhibitors and
suramin decreases invasiveness of breast cancer cells. Breast
Cancer Res Treat. 144:79–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zilli M, Grassadonia A, Tinari N, Di
Giacobbe A, Gildetti S, Giampietro J, Natoli C and Iacobelli S;
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
(CINBO). Molecular mechanisms of endocrine resistance and their
implication in the therapy of breast cancer. Biochim Biophys Acta.
1795:62–81. 2009.
|
|
30
|
Tavares-Valente D, Baltazar F, Moreira R
and Queirós O: Cancer cell bioenergetics and pH regulation
influence breast cancer cell resistance to paclitaxel and
doxorubicin. J Bioenerg Biomembr. 45:467–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hernandez-Aya LF and Gonzalez-Angulo AM:
Adjuvant systemic therapies in breast cancer. Surg Clin North Am.
93:473–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko
CW, Sridhara R, Justice R and Pazdur R: FDA drug approval summary:
Lapatinib in combination with capecitabine for previously treated
metastatic breast cancer that overexpresses HER-2. Oncologist.
13:1114–1119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Payne S and Miles D: Mechanisms of
anticancer drugs. Scott-Brown’s Otorhinolaryngology. Head Neck
Surg. 7:34–46. 2008.
|
|
35
|
Piva M, Domenici G, Iriondo O, Rábano M,
Simões BM, Comaills V, Barredo I, López-Ruiz JA, Zabalza I, Kypta
R, et al: Sox2 promotes tamoxifen resistance in breast cancer
cells. EMBO Mol Med. 6:66–79. 2014. View Article : Google Scholar :
|
|
36
|
Tian W, Chen J, He H and Deng Y: MicroRNAs
and drug resistance of breast cancer: Basic evidence and clinical
applications. Clin Transl Oncol. 15:335–342. 2013. View Article : Google Scholar
|
|
37
|
Chen J, Tian W, Cai H, He H and Deng Y:
Down-regulation of microRNA-200c is associated with drug resistance
in human breast cancer. Med Oncol. 29:2527–2534. 2012. View Article : Google Scholar
|
|
38
|
Chen SJ, Luan J, Zhang HS, Ruan CP, Xu XY,
Li QQ and Wang NH: EGFR-mediated G1/S transition contributes to the
multidrug resistance in breast cancer cells. Mol Biol Rep.
39:5465–5471. 2012. View Article : Google Scholar
|
|
39
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Coley HM: Mechanisms and strategies to
overcome chemotherapy resistance in metastatic breast cancer.
Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van Kouwenhove M, Kedde M and Agami R:
MicroRNA regulation by RNA-binding proteins and its implications
for cancer. Nat Rev Cancer. 11:644–656. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Giuliano M, Schifp R, Osborne CK and
Trivedi MV: Biological mechanisms and clinical implications of
endocrine resistance in breast cancer. Breast. 20(Suppl 3):
S42–S49. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lianos GD, Vlachos K, Zoras O, Katsios C,
Cho WC and Roukos DH: Potential of antibody-drug conjugates and
novel therapeutics in breast cancer management. Onco Targets Ther.
7:491–500. 2014.PubMed/NCBI
|
|
44
|
Ren Z, Li Y, Hameed O, Siegal GP and Wei
S: Prognostic factors in patients with metastatic breast cancer at
the time of diagnosis. Pathol Res Pract. 210:301–306. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Agrawal S: Late effects of cancer
treatment in breast cancer survivors. South Asian J Cancer.
3:112–115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schmitz KH, Prosnitz RG, Schwartz AL and
Carver JR: Prospective surveillance and management of cardiac
toxicity and health in breast cancer survivors. Cancer. 118(Suppl):
S2270–S2276. 2012. View Article : Google Scholar
|
|
47
|
Rao RD and Cobleigh MA: Adjuvant endocrine
therapy for breast cancer. Oncology (Williston Park). 26(6): 541–7.
550552 passim. 2012.
|
|
48
|
Dontu G, El-Ashry D and Wicha MS: Breast
cancer, stem/ progenitor cells and the estrogen receptor. Trends
Endocrinol Metab. 15:193–197. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar
|
|
51
|
Wright MH, Calcagno AM, Salcido CD,
Carlson MD, Ambudkar SV and Varticovski L: Brca1 breast tumors
contain distinct CD44+/CD24− and
CD133+ cells with cancer stem cell characteristics.
Breast Cancer Res. 10:R102008. View Article : Google Scholar
|
|
52
|
Reuben JM, Lee BN, Li C, Gao H, Broglio
KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN,
et al: Circulating tumor cells and biomarkers: Implications for
personalized targeted treatments for metastatic breast cancer.
Breast J. 16:327–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang C, Machiraju R and Huang K: Breast
cancer patient stratification using a molecular regularized
consensus clustering method. Methods. 67:304–312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Crawford S: Anti-inflammatory/antioxidant
use in long-term maintenance cancer therapy: A new therapeutic
approach to disease progression and recurrence. Ther Adv Med Oncol.
6:52–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Harvie M: Nutritional supplements and
cancer: potential benefits and proven harms. Am Soc Clin Oncol Educ
Book. 2014.34:e478–86. View Article : Google Scholar
|
|
56
|
Harris HR, Orsini N and Wolk A: Vitamin C
and survival among women with breast cancer: A meta-analysis. Eur J
Cancer. 50:1223–1231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shishodia S, Chaturvedi MM and Aggarwal
BB: Role of curcumin in cancer therapy. Curr Probl Cancer.
31:243–305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ravindran J, Prasad S and Aggarwal BB:
Curcumin and cancer cells: How many ways can curry kill tumor cells
selectively? AAPS J. 11:495–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hasima N and Aggarwal BB: Targeting
proteasomal pathways by dietary curcumin for cancer prevention and
treatment. Curr Med Chem. 21:1583–1594. 2014. View Article : Google Scholar
|
|
60
|
Karunagaran D, Rashmi R and Kumar TR:
Induction of apoptosis by curcumin and its implications for cancer
therapy. Curr Cancer Drug Targets. 5:117–129. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Calaf GM, Echiburú-Chau C, Wen G, Balajee
AS and Roy D: Effect of curcumin on irradiated and
estrogen-transformed human breast cell lines. Int J Oncol.
40:436–442. 2012.
|
|
62
|
Cridge BJ, Larsen L and Rosengren RJ:
Curcumin and its derivatives in breast cancer: Current developments
and potential for the treatment of drug-resistant cancers. Oncol
Discov. 1:62013. View Article : Google Scholar
|
|
63
|
Terlikowska K, Witkowska A and Terlikowski
S: Curcumin in chemoprevention of breast cancer. Postepy Hig Med
Dosw (Online). 68:571–578. 2014.(In Polish). View Article : Google Scholar
|
|
64
|
Lu P, Weaver VM and Werb Z: The
extracellular matrix: A dynamic niche in cancer progression. J Cell
Biol. 196:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Brücher BL and Jamall IS: Epistemology of
the origin of cancer: A new paradigm. BMC Cancer. 14:3312014.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Meyer AE, Gatza CE, How T, Starr M, Nixon
AB and Blobe GC: The role of TGF-β receptor III localization in
polarity and breast cancer progression. Mol Biol Cell.
25:2291–2304. 2014. View Article : Google Scholar : PubMed/NCBI
|
